High-Sensitive CRP and Carotid Stiffness Between Patients With and Without Coronary Slow Flow
NCT ID: NCT07076745
Last Updated: 2025-07-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
60 participants
OBSERVATIONAL
2025-01-01
2025-07-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
NLR AND CRP Useful as Cost-Effective Preliminary Prognostic Markers in ST-Elevation Myocardial Infarction
NCT06491667
Relation Between Aortic Sclerosis &Severity of Coronary Heart Disease.
NCT06965218
High Sensitive C-reactive Protein to Albumin Ratio in Acute Coronary Syndrome
NCT06673381
Lipid Profile in Acute Coronary Syndrome
NCT05126043
Aortic Stiffness and Distensibility as Predictor to Severity of Coronary Artery Disease
NCT03615963
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Hypothesis: High-sensitivity C-reactive protein (hs-CRP) is a well-established biomarker of systemic inflammation and has been associated with various cardiovascular conditions. Elevated hs-CRP levels have been observed in patients with CSFP, suggesting an inflammatory component in its pathogenesis. This marker not only predicts future cardiovascular events but may also reflect ongoing vascular inflammation in patients with angiographically normal coronary arteries.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study group
Patients diagnosed with coronary slow flow based on corrected thrombolysis in myocardial infarction (TIMI) frame count (cTFC) \>27.
High-sensitivity C-reactive protein
High-sensitivity C-reactive protein will be done.
Stiffness Measurement
Measurements will include carotid intima-media thickness (CIMT), systolic (Ds) and diastolic (Dd) diameters, and calculation of stiffness indices:
* β-stiffness index.
* Peterson's elastic modulus (Ep).
* Distensibility coefficient (DC).
* Compliance coefficient (CC).
* Strain.
Control group
Patients with normal coronary angiographic flow and no obstructive coronary artery disease.
High-sensitivity C-reactive protein
High-sensitivity C-reactive protein will be done.
Stiffness Measurement
Measurements will include carotid intima-media thickness (CIMT), systolic (Ds) and diastolic (Dd) diameters, and calculation of stiffness indices:
* β-stiffness index.
* Peterson's elastic modulus (Ep).
* Distensibility coefficient (DC).
* Compliance coefficient (CC).
* Strain.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
High-sensitivity C-reactive protein
High-sensitivity C-reactive protein will be done.
Stiffness Measurement
Measurements will include carotid intima-media thickness (CIMT), systolic (Ds) and diastolic (Dd) diameters, and calculation of stiffness indices:
* β-stiffness index.
* Peterson's elastic modulus (Ep).
* Distensibility coefficient (DC).
* Compliance coefficient (CC).
* Strain.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Both sexes.
* Patients undergo coronary angiography for evaluation of chest pain or suspected ischemia.
Exclusion Criteria
* History of cardiovascular events such as myocardial infarction or stroke.
* Diagnosed autoimmune disorders, chronic hepatic or renal diseases.
* Current or recent infections.
* History of malignancy.
* Patients taking medications known to affect inflammatory markers (e.g., corticosteroids or immunosuppressants).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sohag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Remon Saleh Adly
Lecturer of Cardiovascular, Faculty of Medicine, Sohag University, Sohag, Egypt.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sohag University
Sohag, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Soh-Med-25-5-6PD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.